Argenica Therapeutics Limited (ASX:AGN) Annual Report 2021

The latest annual report of Argenica Therapeutics Limited (AGN) was published on 30 Jun 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - AGN Annual Results

Amounts in AUD

Total Revenue
Gross Profit
Net Tangible Assets
Net Income
Capital Expenditures

AGN Income Statement 2021 Annual Report

As per the latest Income Statement of AGN, the Net revenue increased by $NaN (NaN%) compared to the previous period. The operating income in 2021 decreased by $-371940 (-57%). The net income as per the annual report was -1.03M which decreased by $-372239 (-57%) compared to previous year.

Income Statement Report (2021/2020)

Total Revenue296.07k-
Gross Profit296.07k-
Operating Income-1.03M-657.69k
Income Before Tax-1.03M-657.26k
Net Income-1.03M-657.26k

Balance Sheet - AGN 2021 Annual Report

Read further: AGN Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Argenica Therapeutics Limited showed the company increased the cash on balance sheet by $6.80M (1989%). The Net tangible assets of AGN on the balance sheet were at 6.85M which is $6.83M (39250%) more than previous annual report. The total stockholder equity also increased by $6.83M (37117%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

Total Assets7.27M 377.66k
Long Term Debt--
Total Liabilities425.72k 359.26k
Total Shareholder Equity6.85M18.4k
Net Tangible Assets6.85M17.4k

Cash Flow Statement - AGN 2021 Annual Report

The 2021 annual cash flow statement of Argenica Therapeutics Limited showed that the net income decreased by $-372239 (-57%) compared to previous reporting period. Also the capital expenditure of AGN increased by $NaN (NaN%).

As of 2021, the total cash from investing activities was - and total cash from financing activities was 7.85M.

Cash Flow Statement Report (2021/2020)

Net Income-1.03M-657.26k
Capital Expenditures--
Dividends Paid--
Total Cash From From Investing Activities--
Total Cash From From Financing Activities7.85M687.09k

Argenica Therapeutics Limited Annual Report History

Income Statement

Income Statement history of Argenica Therapeutics Limited (ASX:AGN)

30 Jun 202130 Jun 2020
Total Revenue296.07k-
Cost Of Revenue--
Gross Profit296.07k-
Research Development416.05k570.83k
Selling General Administrative641.44k86.86k
Non Recurring--
Other Operating Expenses--
Total Operating Expenses1.33M657.69k
Operating Income-1.03M-657.69k
Total Other Income Expense Net182427
Interest Expense-20-20
Income Before Tax-1.03M-657.26k
Income Tax Expense54-
Minority Interest--
Net Income From Continuing Ops-1.03M-657.26k
Discontinued Operations--
Extraordinary Items--
Effect Of Accounting Charges--
Other Items--
Net Income-1.03M-657.26k
Net Income Applicable To Common Shares-1.03M-657.26k

Balance Sheet Statement

Balance Sheet Statement history of Argenica Therapeutics Limited (ASX:AGN)

30 Jun 202130 Jun 2020
Net Receivables78.08k34.58k
Total Current Assets7.27M376.66k
Intangible Assets1k1k
Total Assets7.27M377.66k
Accounts Payable373.58k353.26k
Other Current Liab14.42k-
Total Current Liabilities425.72k359.26k
Total Liab425.72k359.26k
Common Stock8.05M401.8k
Retained Earnings-1.41M-383.4k
Treasury Stock208.64k-
Other Stockholder Equity208.64k-
Total Stockholder Equity6.85M18.4k
Net Tangible Assets6.85M17.4k
Long Term Debt--

Cash Flow Statement

Cash Flow Statement history of Argenica Therapeutics Limited (ASX:AGN)

30 Jun 202130 Jun 2020
Net Income-1.03M-657.26k
Change To Netincome268.22k268.22k
Change To Account Receivables-92.6k-59.45k
Change To Liabilities-199.72k615.88k
Change To Operating Activities7.19k7.19k
Total Cash From Operating Activities-1.05M-100.83k
Other Cashflows From Financing Activities120120
Total Cash From Financing Activities7.85M687.09k
Change In Cash6.8M586.26k
Issuance Of Stock7.85M687.09k
Capital Expenditures--
Dividends Paid--
Total Cashflows From Investing Activities--